IRIX Stock Analysis: Buy, Sell, or Hold?
IRIX - Iridex Corp
$0.82
-0.01 (-1.39%)
▼
5d:
-7.95%
30d:
-29.91%
90d:
-20.39%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
8d
Get Alerted When IRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IRIX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IRIX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: IRIX is currently trading at $0.82, which is considered oversold relative to its 30-day fair value range of $0.90 to $1.14. From a valuation perspective, the stock is trading at a discount (Forward PE: 41.0) compared to its historical average (54.4). Remarkably, the market is currently pricing in an annual earnings decline of 9.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, IRIX is in a downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.75 (+235.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IRIX is in a downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.75 (+235.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.90 -
$1.14
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 235.4% below Wall St target ($2.75)
- CAUTION: Recommendation downgraded due to -7.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.90 -
$1.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$0.94
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
41.00
Wall Street Target
$2.75
(+235.4%)
Revenue Growth (YoY)
-0.8%
Profit Margin
-6.2%
Valuation Discount vs History
-9.0% cheaper
PE vs Historical
41.0 vs 54.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.0%
(market-implied from PE analysis)
1-Year Target
$0.75
(-9%)
2-Year Target
$0.68
(-17%)
3-Year Target
$0.62
(-25%)
3-Yr Target (if PE normalizes)
(PE: 41→54)
$0.82
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 41.0 to 54.4
Stabilization Target:
$1.09
(+32.7%)
PE Expansion Potential:
+32.7%
Share & Embed Analysis
Last updated: August 02, 2026 2:47 PM ET
Data refreshes hourly during market hours. Next update: 3:47 PM
Data refreshes hourly during market hours. Next update: 3:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$93 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$384 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 52 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$99 | 60 HOLD |
